Drug intelligence / Profile preview

[225Ac]Ac-DOTA-14.G2a

Development stage
Preclinical
Lead developer
University of British Columbia
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

[225Ac]Ac-DOTA-14.G2a is a preclinical targeted alpha therapy (TAT) radiopharmaceutical consisting of the murine anti-ganglioside GD2 monoclonal antibody 14.G2a conjugated to the chelator DOTA and radiolabeled with the alpha-emitting radionuclide actinium-225 ([225Ac]Ac) [EP-0068]. Developed by researchers at the University of British Columbia, TRIUMF, and collaborating institutions, the construct is designed to target GD2, a tumor-associated surface antigen highly expressed in neuroblastoma and other solid tumors. Upon binding to GD2 on cancer cells, the radiopharmaceutical delivers highly localized, high-energy alpha radiation, inducing lethal double-strand DNA breaks in the target cells while minimizing damage to surrounding healthy tissues. Preclinical studies focus on evaluating its biodistribution, intratumoral activity mapping, and the redistribution of its decay daughters (such as bismuth-213) to clearance organs [EP-0068].

Other names
225Ac-DOTA-14.G2a225Ac-DOTA-14G2a[225Ac]Ac-DOTA-14G2aactinium-225 DOTA-14.G2aactinium225 DOTA-14.G2aactinium 225 DOTA-14.G2a
02

Identity

Drug type
Antibody-Based Therapeutics
Modality
Monoclonal AntibodiesAntibody-Radionuclide ConjugatesAlpha Emitters
03

Pharmacology

Targets

Route
Intravenous
04

Development

IndicationHighest phaseStatus
neuroblastomaPreclinicalActive
neuroblastoma (MYCN-amplified / non-amplified)PreclinicalActive

Every indication, with countries and timelines, is in the full profile.

05

Regulatory

MarketStatusYear
United StatesNot approved—
European UnionNot approved—
ChinaNot approved—
JapanNot approved—

Approved indications and other markets are in the full profile.

06

Companies

  • University of British ColumbiaLead developer
07

Competitive landscape

Drugs on the same target
40
Drugs in the lead indication
226

Lead indication: neuroblastoma

Most advanced in the lead indication

  1. dinutuximabApproved
  2. naxitamabApproved
  3. cyclophosphamideApproved
  4. doxorubicinApproved
  5. eflornithineApproved

Beyond the preview

Go deeper on [225Ac]Ac-DOTA-14.G2a.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on [225Ac]Ac-DOTA-14.G2a.

Work on [225Ac]Ac-DOTA-14.G2a? Claim this page to correct or add information. Claim this page

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call